title: DNA methylation profiles at precancerous stages associated with recurrence of lung adenocarcinoma.
abstract: The aim of this study was to clarify the significance of DNA methylation alterations at precancerous stages of lung adenocarcinoma. Using single-CpG resolution Infinium array, genome-wide DNA methylation analysis was performed in 36 samples of normal lung tissue obtained from patients without any primary lung tumor, 145 samples of non-cancerous lung tissue (N) obtained from patients with lung adenocarcinomas, and 145 samples of tumorous tissue (T). Stepwise progression of DNA methylation alterations from normal lung tissue to non-cancerous lung tissue obtained from patients with lung adenocarcinomas, and then tumorous tissue samples, was observed at 3,270 CpG sites, suggesting that non-cancerous lung tissue obtained from patients with lung adenocarcinomas was at precancerous stages with DNA methylation alterations. At CpG sites of 2,083 genes, DNA methylation status in samples of non-cancerous lung tissue obtained from patients with lung adenocarcinomas was significantly correlated with recurrence after establishment of lung adenocarcinomas. Among such recurrence-related genes, 28 genes are normally unmethylated (average β-values based on Infinium assay in normal lung tissue samples was less than 0.2) and their DNA hypermethylation at precancerous stages was strengthened during progression to lung adenocarcinomas (Δβ(T-N)>0.1). Among these 28 genes, we focused on 6 for which implications in transcription regulation, apoptosis or cell adhesion had been reported. DNA hypermethylation of the ADCY5, EVX1, GFRA1, PDE9A, and TBX20 genes resulted in reduced mRNA expression in tumorous tissue samples. 5-Aza-2'-deoxycytidine treatment of lung cancer cell lines restored the mRNA expression levels of these 5 genes. Reduced mRNA expression in tumorous tissue samples was significantly correlated with tumor aggressiveness. These data suggest that DNA methylation alterations at precancerous stages determine tumor aggressiveness and outcome through silencing of specific genes.
authors.affiliation: Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Sato
authors.forename: Eri
authors.initials: E
authors.lastname: Arai
authors.forename: Takashi
authors.initials: T
authors.lastname: Kohno
authors.forename: Koji
authors.initials: K
authors.lastname: Tsuta
authors.forename: Shun-ichi
authors.initials: S
authors.lastname: Watanabe
authors.forename: Kenzo
authors.initials: K
authors.lastname: Soejima
authors.forename: Tomoko
authors.initials: T
authors.lastname: Betsuyaku
authors.forename: Yae
authors.initials: Y
authors.lastname: Kanai
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology*; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001374:Azacitidine / Q000494:pharmacology; D019175:DNA Methylation / Q000187:drug effects / Q000235:genetics*; D015342:DNA Probes / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D020868:Gene Silencing; D052138:Genes, Neoplasm / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics* / Q000473:pathology*; D009367:Neoplasm Staging; D011230:Precancerous Conditions / Q000235:genetics* / Q000473:pathology*; D016016:Proportional Hazards Models; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism
chemical_list: D015342:DNA Probes; D012333:RNA, Messenger; D001374:Azacitidine
references.citation: Int J Oncol. 2012 Mar;40(3):739-46
references.pmid: 22076605
references.citation: Circulation. 2007 Oct 16;116(16):1776-83
references.pmid: 17893275
references.citation: Epigenomics. 2009 Oct;1(1):177-200
references.pmid: 22122642
references.citation: Am J Respir Crit Care Med. 2009 Mar 1;179(5):396-401
references.pmid: 19096006
references.citation: Genome Res. 2012 Jul;22(7):1197-211
references.pmid: 22613842
references.citation: Hum Mol Genet. 2011 Jul 1;20(13):2591-602
references.pmid: 21487021
references.citation: Int J Cancer. 2003 Nov 20;107(4):612-6
references.pmid: 14520700
references.citation: Cancer. 1995 Jun 15;75(12):2844-52
references.pmid: 7773933
references.citation: Carcinogenesis. 2009 Feb;30(2):214-21
references.pmid: 19037089
references.citation: Carcinogenesis. 2012 Aug;33(8):1487-93
references.pmid: 22610075
references.citation: J Thorac Oncol. 2011 Feb;6(2):244-85
references.pmid: 21252716
references.citation: Nat Neurosci. 2007 Mar;10(3):293-300
references.pmid: 17310246
references.citation: Nat Rev Cancer. 2011 Sep 23;11(10):726-34
references.pmid: 21941284
references.citation: Cancer Metastasis Rev. 2010 Mar;29(1):95-107
references.pmid: 20099008
references.citation: J Cell Biol. 2003 Sep 15;162(6):1149-60
references.pmid: 12963709
references.citation: Respirology. 2012 Jan;17(1):50-65
references.pmid: 22040022
references.citation: Lung Cancer. 2012 Apr;76(1):106-11
references.pmid: 21983100
references.citation: Leukemia. 2008 Aug;22(8):1529-38
references.pmid: 18528427
references.citation: PLoS One. 2012;7(5):e37775
references.pmid: 22629454
references.citation: Cancer Biol Ther. 2008 Jul;7(7):1146-56
references.pmid: 18535405
references.citation: Cancer Res. 1997 Nov 1;57(21):4913-5
references.pmid: 9354457
references.citation: Lancet Oncol. 2011 Feb;12(2):175-80
references.pmid: 21277552
references.citation: Dig Dis. 2011;29(2):130-5
references.pmid: 21734376
references.citation: Carcinogenesis. 2012 Jul;33(7):1270-6
references.pmid: 22510280
references.citation: Epigenetics Chromatin. 2012 Jun 22;5(1):9
references.pmid: 22726460
references.citation: Pathol Int. 2008 Sep;58(9):544-58
references.pmid: 18801069
references.citation: Genes Cancer. 2010 Dec;1(12):1200-10
references.pmid: 21779443
references.citation: Int J Cancer. 2006 Jul 15;119(2):288-96
references.pmid: 16453286
references.citation: Cell. 2007 Jul 27;130(2):247-58
references.pmid: 17662940
references.citation: Dev Biol. 2012 Mar 1;363(1):234-46
references.pmid: 22226977
references.citation: Cell Prolif. 2012 Jun;45(3):199-206
references.pmid: 22469131
references.citation: Diagn Mol Pathol. 2012 Jun;21(2):93-104
references.pmid: 22555092
references.citation: Br J Cancer. 2012 Jun 26;107(1):100-7
references.pmid: 22596233
references.citation: Epigenetics. 2010 Aug 16;5(6):499-508
references.pmid: 20484983
references.citation: J Biol Chem. 1998 Jun 19;273(25):15559-64
references.pmid: 9624146
references.citation: Cancer Sci. 2010 Jan;101(1):36-45
references.pmid: 19891661
references.citation: J Biol Chem. 1995 Nov 17;270(46):27695-701
references.pmid: 7499236
references.citation: N Engl J Med. 2008 Mar 13;358(11):1118-28
references.pmid: 18337602
references.citation: Carcinogenesis. 2007 Dec;28(12):2434-42
references.pmid: 17893234
references.citation: Oncogene. 2010 Nov 18;29(46):6138-48
references.pmid: 20711234
references.citation: Clin Cancer Res. 2012 May 15;18(10):2976-86
references.pmid: 22434665